PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension
Pulmonary HypertensionGlobal HealthPVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up...
Pulmonary HypertensionRecruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.
Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures
Pulmonary HypertensionThe objective of this proposal is to study circulating and echocardiographic markers of pulmonary vascular and right ventricular remodeling in patients with a WHO-2 diagnosis of pulmonary hypertension after mitral valve procedures. The investigators are proposing the study will be impactful for the early detection and prediction and of residual pulmonary hypertension (PH) that would otherwise be undetected and fatal with no curative treatment.
Pulmonary Hypertension Biorepository and Registry
Pulmonary HypertensionPulmonary Arterial Hypertension14 moreEstablish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
Glucocorticoids and Pulmonary Hypertension
Pulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary Hypertension1 morePediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever expanding body of knowledge indicates the important contribution of inflammation to pathogenesis and successful treatment with glucocorticoids. Over the last several years the investigators have utilized steroids in patients with severe pulmonary hypertension as part of a treatment regimen. These basic science studies possibly identifies a biochemical etiology for the development of disease and may also be impacted by the administration of steroids. Additionally, there is a commercially available assay which tests for all of the above molecules.
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary...
Pulmonary HypertensionChronic Thromboembolic Pulmonary Hypertension1 morecardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
Incidence and Clinical Characteristics of Pulmonary Hypertension Secondary to ARDS in the Highland...
ARDSThe study is conducted in the affiliated hospital of Qinghai University .Patients in the department of Critical Care Medicine and Emergency Intensive Care Unit will be eligible for inclusion if they meet the Berlin criteria.Two researchers assess pulmonary artery pressure and right heart function of patients who are enrolled.
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
Chronic Thromboembolic Pulmonary HypertensionPulmonary Arterial HypertensionThe BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland. All patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension confirmed in right heart catheterization, will be eligible to participate in the study.
Pulmonary Hypertension Association Registry
Pulmonary Arterial HypertensionChronic Thromboembolic Pulmonary Hypertension1 moreThe PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.
Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation
Pulmonary HypertensionKidney Transplantation1 moreThe aim of the study is to investigate pulmonary hemodynamics at rest and during exercise in patients before and after kidney transplantation.